A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BMS-986489 in Chinese Participants With Relapsed/Refractory Small Cell Lung Cancer
← catalyst calendarNCT06799286 · readout in 280 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
10estimated
Sites
5
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-07 | actual | When the study began enrolling |
| Primary completion | 2027-05-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-26 | estimated | The whole study's end, after follow-up |
| First posted | 2025-01-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Small Cell Lung Carcinoma
Intervention
- Drug: BMS-986489
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Up to 19 months after last participant's first treatment
Number of participants with Serious AEs (SAEs)
measured Up to 19 months after last participant's first treatment
Number of participants with AEs leading to discontinuation of study treatment
measured Up to 19 months after last participant's first treatment
Number of participants with select AEs
measured Up to 19 months after last participant's first treatment
Number of participants with immune-mediated AEs (IMAEs)
measured Up to 19 months after last participant's first treatment
Number of deaths
measured Up to 19 months after last participant's first treatment
Number of participants with laboratory abnormalities
measured Up to 19 months after last participant's first treatment
Maximum observed concentration (Cmax) for BMS-986012
measured Up to 19 months after last participant's first treatment
Time of maximum observed concentration (Tmax) for BMS-986012
measured Up to 19 months after last participant's first treatment
Trough observed plasma concentration (Ctrough) for BMS-986012
measured Up to 19 months after last participant's first treatment
Concentration at the end of a dosing interval (Ctau) for BMS-986012
measured Up to 19 months after last participant's first treatment
Average concentration over a dosing interval ([AUC(TAU)/TAU]) (Cavg(TAU)) for BMS-986012
measured Up to 19 months after last participant's first treatment
Area under the concentration-time curve within one dosing interval (AUC(TAU)) for BMS-986012
measured Up to 19 months after last participant's first treatment
Total body clearance (CLT) for BMS-986012
measured Up to 19 months after last participant's first treatment
Observed concentration at end of infusion (Ceoi) for BMS-986012
measured Up to 19 months after last participant's first treatment
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed